93340 Federal Register / Vol. 89, No. 228 / Tuesday, November 26, 2024 / Notices 

Commission’s Rules of Practice and 

Procedure, part 201, subparts A and B 

(19 CFR part 201), and part 207, 

subparts A and C (19 CFR part 207). 

Participation in the investigations and 

public service list.—Persons, including 

industrial users of the subject 

merchandise and, if the merchandise is 

sold at the retail level, representative 

consumer organizations, wishing to 

participate in the final phase of these 

investigations as parties must file an 

entry of appearance with the Secretary 

to the Commission, as provided in 

§ 201.11 of the Commission’s rules, no 

later than 21 days prior to the hearing 

date specified in this notice. A party 

that filed a notice of appearance during 

the preliminary phase of the 

investigations need not file an 

additional notice of appearance during 

this final phase. The Secretary will 

maintain a public service list containing 

the names and addresses of all persons, 

or their representatives, who are parties 

to the investigations. 

Please note the Secretary’s Office will 

accept only electronic filings during this 

time. Filings must be made through the 

Commission’s Electronic Document 

Information System (EDIS, https://

edis.usitc.gov). No in-person paperbased filings or paper copies of any 

electronic filings will be accepted until 

further notice. 

Limited disclosure of business 

proprietary information (BPI) under an 

administrative protective order (APO) 

and BPI service list.—Pursuant to 

§ 207.7(a) of the Commission’s rules, the 

Secretary will make BPI gathered in the 

final phase of these investigations 

available to authorized applicants under 

the APO issued in the investigations, 

provided that the application is made 

no later than 21 days prior to the 

hearing date specified in this notice. 

Authorized applicants must represent 

interested parties, as defined by 19 

U.S.C. 1677(9), who are parties to the 

investigations. A party granted access to 

BPI in the preliminary phase of the 

investigations need not reapply for such 

access. A separate service list will be 

maintained by the Secretary for those 

parties authorized to receive BPI under 

the APO. 

Staff report.—The prehearing staff 

report in the final phase of these 

investigations will be placed in the 

nonpublic record on March 19, 2025, 

and a public version will be issued 

thereafter, pursuant to § 207.22 of the 

Commission’s rules. 

Hearing.—The Commission will hold 

a hearing in connection with the final 

phase of these investigations beginning 

at 9:30 a.m. on Tuesday, April 1, 2025. 

Requests to appear at the hearing should 

be filed in writing with the Secretary to 

the Commission on or before Thursday, 

March 27, 2025. Any requests to appear 

as a witness via videoconference must 

be included with your request to appear. 

Requests to appear via videoconference 

must include a statement explaining 

why the witness cannot appear in 

person; the Chairman, or other person 

designated to conduct the 

investigations, may in their discretion 

for good cause shown, grant such a 

request. Requests to appear as remote 

witness due to illness or a positive 

COVID–19 test result may be submitted 

by 3:00 p.m. the business day prior to 

the hearing. Further information about 

participation in the hearing will be 

posted on the Commission’s website at 

https://www.usitc.gov/calendarpad/ 

calendar.html. 

A nonparty who has testimony that 

may aid the Commission’s deliberations 

may request permission to present a 

short statement at the hearing. All 

parties and nonparties desiring to 

appear at the hearing and make oral 

presentations should attend a 

prehearing conference, if deemed 

necessary, to be held at 9:30 a.m. on 

Friday, March 28, 2025. Parties shall file 

and serve written testimony and 

presentation slides in connection with 

their presentation at the hearing by no 

later than noon on March 31, 2025. Oral 

testimony and written materials to be 

submitted at the public hearing are 

governed by sections 201.6(b)(2), 

201.13(f), and 207.24 of the 

Commission’s rules. Parties must submit 

any request to present a portion of their 

hearing testimony in camera no later 

than 7 business days prior to the date of 

the hearing. 

Written submissions.—Each party 

who is an interested party shall submit 

a prehearing brief to the Commission. 

Prehearing briefs must conform with the 

provisions of § 207.23 of the 

Commission’s rules; the deadline for 

filing is March 26, 2025. Parties shall 

also file written testimony in connection 

with their presentation at the hearing, 

and posthearing briefs, which must 

conform with the provisions of § 207.25 

of the Commission’s rules. The deadline 

for filing posthearing briefs is April 8, 

2025. In addition, any person who has 

not entered an appearance as a party to 

the investigations may submit a written 

statement of information pertinent to 

the subject of the investigations, 

including statements of support or 

opposition to the petition, on or before 

April 8, 2025. On April 23, 2025, the 

Commission will make available to 

parties all information on which they 

have not had an opportunity to 

comment. Parties may submit final 

comments on this information on or 

before April 25, 2025, but such final 

comments must not contain new factual 

information and must otherwise comply 

with § 207.30 of the Commission’s rules. 

All written submissions must conform 

with the provisions of § 201.8 of the 

Commission’s rules; any submissions 

that contain BPI must also conform with 

the requirements of §§ 201.6, 207.3, and 

207.7 of the Commission’s rules. The 

Commission’s Handbook on Filing 

Procedures, available on the 

Commission’s website at https://

www.usitc.gov/documents/handbook_

on_filing_procedures.pdf, elaborates 

upon the Commission’s procedures with 

respect to filings. 

Additional written submissions to the 

Commission, including requests 

pursuant to § 201.12 of the 

Commission’s rules, shall not be 

accepted unless good cause is shown for 

accepting such submissions, or unless 

the submission is pursuant to a specific 

request by a Commissioner or 

Commission staff. 

In accordance with §§ 201.16(c) and 

207.3 of the Commission’s rules, each 

document filed by a party to the 

investigations must be served on all 

other parties to the investigations (as 

identified by either the public or BPI 

service list), and a certificate of service 

must be timely filed. The Secretary will 

not accept a document for filing without 

a certificate of service. 

Authority: These investigations are 

being conducted under authority of title 

VII of the Tariff Act of 1930; this notice 

is published pursuant to § 207.21 of the 

Commission’s rules. 

By order of the Commission. 

Issued: November 20, 2024. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2024–27687 Filed 11–25–24; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1456] 

Importer of Controlled Substances 

Application: Experic LLC 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Experic LLC to be registered 

as an importer of basic class(es) of 

controlled substance(s). Refer to 

SUPPLEMENTARY INFORMATION listed 

below for further drug information. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 228 / Tuesday, November 26, 2024 / Notices 93341 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants, therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before December 26, 2024. Such 

persons may also file a written request 

for a hearing on the application on or 

before December 26, 2024. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. All 

requests for a hearing must be sent to: 

(1) Drug Enforcement Administration, 

Attn: Hearing Clerk/OALJ, 8701 

Morrissette Drive, Springfield, Virginia 

22152; and (2) Drug Enforcement 

Administration, Attn: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing should 

also be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on October 17, 2024, 

Experic LLC, 2 Clarke Drive, Cranbury, 

New Jersey 08512–3619, applied to be 

registered as an importer of the 

following basic class(es) of controlled 

substance(s): 

Controlled substance Drug code Schedule 

Nabilone ............ 7379 II 

The company plans to import drug 

code Nabilone (7379) for clinical trial 

purposes. No other activity for this drug 

code is authorized for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

Matthew Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2024–27673 Filed 11–25–24; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1453] 

Bulk Manufacturer of Controlled 

Substances Application: Cayman 

Chemical Company 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Cayman Chemical Company 

has applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

Supplementary Information listed below 

for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants, therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before January 27, 2025. Such 

persons may also file a written request 

for a hearing on the application on or 

before January 27, 2025. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on August 8, 2024, 

Cayman Chemical Company, 1180 East 

Ellsworth Road, Ann Arbor, Michigan 

48108–2419, applied to be registered as 

a bulk manufacturer of the following 

basic class(es) of controlled 

substance(s): 

Controlled substance Drug code Schedule 

3-Fluoro-N-methylcathinone (3-FMC) ........................................................................................................................ 1233 I 

Cathinone .................................................................................................................................................................. 1235 I 

Methcathinone ........................................................................................................................................................... 1237 I 

4-Fluoro-N-methylcathinone (4-FMC) 1238 I N ........................................................................................................ 1238 I 

Para-Methoxymethamphetamine (PMMA), 1-(4-methoxyphenyl)-N-methylpropan-2-amine .................................... 1245 I 

Pentedrone (a-methylaminovalerophenone) ............................................................................................................. 1246 I 

Mephedrone (4-Methyl-N-methylcathinone) .............................................................................................................. 1248 I 

4-Methyl-N-ethylcathinone (4-MEC) .......................................................................................................................... 1249 I 

Naphyrone ................................................................................................................................................................. 1258 I 

3-methylmethcathinone (2-(methylamino)-1-(3-methylphenyl)propan-1-one) ........................................................... 1259 I 

N-Ethylamphetamine ................................................................................................................................................. 1475 I 

Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine) 1478 I N ................................................................. 1478 I 

N,N-Dimethylamphetamine ........................................................................................................................................ 1480 I 

Fenethylline ............................................................................................................................................................... 1503 I 

Aminorex .................................................................................................................................................................... 1585 I 

4-Methylaminorex (cis isomer) .................................................................................................................................. 1590 I 

4,4′-Dimethylaminorex (4,4′-DMAR; 4,5-dihydro-4-1595 I N methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine).1595 I 

Gamma Hydroxybutyric Acid ..................................................................................................................................... 2010 I 

Methaqualone ............................................................................................................................................................ 2565 I 

Mecloqualone ............................................................................................................................................................ 2572 I 

Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6Hthieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine ........................... 2780 I 

Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4Hbenzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine) ...................... 2785 I


lotter on DSK11XQN23PROD with NOTICES1